

DAFTAR PUSTAKA

1. Pemerintah Indonesia. Undang-Undang Nomor 36 Tahun 2009 tentang Kesehatan. 2009 p. 3.
2. Djuanda A, Suriadiredja ASD, Sudarmono A, Wiryadi BE, Kurniati DD, Daili ESS. Ilmu Penyakit Kulit dan Kelamin. Edisi Ketujuh. Menaldi SLS, Bramono K, Indriatmi Wresti, editors. Fakultas Kedokteran Universitas Indonesia. Jakarta: Badan Penerbit FKUI; 2016.
3. Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, et al. International Consensus on drug allergy. *Allergy: European Journal of Allergy and Clinical Immunology*. 2014;69(4):420–37.
4. Brockow K, Ardern-Jones MR, Mockenhaupt M, Aberer W, Barbaud A, Caubet JC, et al. EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity. *Allergy: European Journal of Allergy and Clinical Immunology*. 2019 Jan 1;74(1):14–27.
5. Kumar R, Singh S, Arora S, Bhati S. Adverse drug reactions: a comprehensive review. *Journal of Drug Delivery and Therapeutics*. 2018;8(1):103–7.
6. Verma R, Tiwari D, Gupta D, Verma N. Cutaneous Adverse Drug Reactions- A Study of Clinical Patterns, Causality, Severity & Preventability [Internet]. Vol. 13, *IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)* e-ISSN. 2014. Available from: www.iosrjournals.org
7. Shadab M. To Study and Evaluate the Incidence of Cutaneous Adverse Drug Reaction (CADRS) in the Patients Attending Dermatology Department of A Tertiary Care Teaching Hospital. *Journal of Medical science and clinical research* [Internet]. 2017 Jul 7;5(7). Available from: <http://jmscr.igmpublication.org/v5-i7/10%20jmscr.pdf>
8. Nayan Singh K. Morbidity and Mortality of Adverse Drug Reactions. *J Pharmacovigil*. 2021;1.
9. Mayorga C, Fernandez TD, Montañez MI, Moreno E, Torres MJ. Recent developments and highlights in drug hypersensitivity. Vol. 74, *Allergy: European Journal of Allergy and Clinical Immunology*. Blackwell Publishing Ltd; 2019. p. 2368–81.
10. Khan DA, Solensky R. Drug allergy. *Journal of Allergy and Clinical Immunology*. 2010;125(2 SUPPL. 2).
11. Damayanti D. Konsep Patomekanisme Erupsi Obat Terkini. *Berkala Ilmu Kesehatan Kulit Dan Kelamin*. 2019;31(3):236–41.
12. Hamm RL. Drug Allergy: Delayed Cutaneous Hypersensitivity Reactions to Drugs. *EMJ Allergy & Immunology* [Internet]. 2016 Aug 2 [cited 2023 Jan

- 18];1(1):92–101. Available from: <https://www.emjreviews.com/allergy-immunology/article/drug-allergy-delayed-cutaneous-hypersensitivity-reactions-to-drugs/>
13. Yang F, Chen Z, Chen S an, Zhu Q, Wang L, Xiong H, et al. Clinical profile of cutaneous adverse drug reactions: a retrospective study of 1883 hospitalized patients from 2007 to 2016 in Shanghai, China. *European Journal of Dermatology*. 2020 Jan 1;30(1):24–31.
 14. Patel T, Thakkar S, Sharma D. Cutaneous adverse drug reactions in Indian population: A systematic review. *Indian Dermatol Online J*. 2014;5(6):76.
 15. Choon SE, Lai NM. An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. *Indian J Dermatol Venereol Leprol*. 2012 Nov;78(6):734–9.
 16. Tanzira D, Batubara DE, Andriani N, Suryani D. Profil Erupsi Obat di RSUD Dr.Pirngadi Kota Medan Tahun 2015-2017 [Internet]. Fakultas Kedokteran Universitas Muhammadiyah Sumatera Utara; 2019 [cited 2022 Nov 6]. Available from: <http://repository.umsu.ac.id/bitstream/handle/123456789/5453/1508260014.pdf?sequence=1>
 17. Gaya ML, Akhyar G. Studi retrospektif erupsi obat alergik di RS dr. M. Djamil Padang periode Januari 2014 – Desember 2016. *Jurnal Kesehatan Andalas* [Internet]. 2018;7. Available from: <http://jurnal.fk.unand.ac.id>
 18. Bellón T. Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances. Vol. 42, *Drug Safety*. Springer International Publishing; 2019. p. 973–92.
 19. Damayanti D, Umborowati MA, Anggraeni S, CRS P, M H, H S. Clinicoepidemiological Profile of Severe Cutaneous Adverse Drug Reaction: A Retrospective Study. *Berkala Ilmu Kesehatan Kulit Dan Kelamin*. 2019;
 20. Zhao J, Hu L, Zhang L, Zhou M, Gao L, Cheng L. Causative drugs for drug-induced cutaneous reactions in central China: a 608-case analysis. *An Bras Dermatol*. 2019 Nov 1;94(6):664–70.
 21. Ayu D, Oktarina M, Sophiati M, Maharani E, Moha R, Waskito F, et al. A Five-Year Review of Adverse Cutaneous Drug Reaction in a Tertiary Care Hospital in Yogyakarta, Indonesia. 2021.
 22. Gomes ER, Geraldes L, Gaspar Â, Malheiro D, Cadinha S, Abreu C, et al. Hypersensitivity Reactions to Nonsteroidal Anti-Inflammatory Drugs among Adults: Clinical Features and Risk Factors for Diagnosis Confirmation. *Int Arch Allergy Immunol*. 2017 Jan 1;171(3–4):269–75.

23. Abou-Taleb DAE, El-Sayed AM, Ghabesha AA, Hassan SB. Severe cutaneous adverse drug reactions: Incidence, clinical patterns, causative drugs and modalities of treatment in Assiut University Hospital, Upper Egypt. *Dermatol Ther.* 2020 Nov 1;33(6).
24. Sasidharanpillai S, Riyaz N, Khader A, Rajan U, Binitha M, Sureshan D. Severe cutaneous adverse drug reactions: A clinicoepidemiological study. *Indian J Dermatol* [Internet]. 2015 Jan 1 [cited 2022 Nov 25];60(1):102. Available from: <http://www.e-ijd.org/text.asp?2015/60/1/102/147834>
25. Erku DA, Mekuria AB, Surur AS, Gebresillassie BM. Extent of dispensing prescription-only medications without a prescription in community drug retail outlets in Addis Ababa, Ethiopia: A simulated-patient study. *Drug Healthc Patient Saf.* 2016 Jul 14;8:65–70.
26. Halid M. Hubungan Tingkat Pendapatan dan Pengetahuan Pasien Terhadap Pembelian Obat Keras tanpa Resep. *Jurnal Farmasi Higea* [Internet]. 2022;14(2). Available from: www.jurnalfarmasihigea.org
27. Rokhman MR, Widiastuti M, Satibi RF, Fatmawati N. PENYERAHAN OBAT KERAS TANPA RESEP DI APOTEK DISPENSING PRESCRIPTION MEDICINES WITHOUT A PRESCRIPTION IN PHARMACY. 2017;7(3).
28. Alfares I, Javaid MS, Chen Z, Anderson A, Antonic-Baker A, Kwan P. Sex Differences in the Risk of Cutaneous Adverse Drug Reactions Induced by Antiseizure Medications: A Systematic Review and Meta-analysis. Vol. 35, *CNS Drugs.* Adis; 2021. p. 161–76.
29. Giefing-Kröll C, Berger P, Lepperdinger G, Grubeck-Loebenstien B. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Vol. 14, *Aging Cell.* 2015. p. 309–21.
30. Gomes ER, Kuyucu S. Epidemiology and Risk Factors in Drug Hypersensitivity Reactions. Vol. 4, *Current Treatment Options in Allergy.* Springer Nature; 2017. p. 239–57.
31. World Health Organization technical report series. International drug monitoring: the role of national centres. 1972;498:1–25.
32. Demoly P, Hillaire-Buys D. Classification and epidemiology of hypersensitivity drug reactions. Vol. 24, *Immunology and Allergy Clinics of North America.* 2004. p. 345–56.
33. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of Adverse Drug Events and Potential Adverse Drug Events: Implications for Prevention. *JAMA* [Internet]. 1995 Jul 5;274(1):29–34. Available from: <https://doi.org/10.1001/jama.1995.03530010043033>

34. Fiszenson-Albala F, Auzerie V, Make E, Farinotti R, Durand-Stocco C, Crickx B, et al. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. *British Journal of Dermatology*. 2003 Nov;149(5):1018–22.
35. Hernandez-Salazar A, de Leon-Rosales SP, Rangel-Frausto S, Criollo E, Archer-Dubon C, Orozco-Topete R. Epidemiology of Adverse Cutaneous Drug Reactions. A Prospective Study in Hospitalized Patients. *Arch Med Res*. 2006 Oct;37(7):899–902.
36. Park CS, Kim TB, Kim SL, Kim JY, Yang KA, Bae YJ, et al. The use of an electronic medical record system for mandatory reporting of drug hypersensitivity reactions has been shown to improve the management of patients in the university hospital in Korea. *Pharmacoepidemiol Drug Saf*. 2008 Sep;17(9):919–25.
37. Han JE, Ye YM, Lee S. Epidemiology of drug hypersensitivity reactions using 6-year national health insurance claim data from Korea. *Int J Clin Pharm*. 2018 Oct 1;40(5):1359–71.
38. Thong BYH, Lucas M, Kang HR, Chang YS, Li PH, Tang MM, et al. Drug hypersensitivity reactions in Asia: regional issues and challenges. *Asia Pac Allergy*. 2020;10(1).
39. Thong BYH, Tan TC. Epidemiology and risk factors for drug allergy. *Br J Clin Pharmacol*. 2011 May;71(5):684–700.
40. Alhawassi TM, Krass I, Bajorek B, Pont LG. A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. Vol. 9, *Clinical Interventions in Aging*. Dove Medical Press Ltd.; 2014. p. 2079–86.
41. Kumar Mudigubba M, Dahiya S, Mudigubba MK, Rajashekarachari Y. RISK FACTORS ASSOCIATED WITH ADVERSE DRUG REACTIONS IN HOSPITALIZED PATIENTS. Article in *International Journal of Pharmaceutical Sciences and Research* [Internet]. 2017;8(9):3847–54. Available from: www.ijpsr.com
42. Mudigubba MK, Murthy MK, Swaroop AM, Nayantara M, Dahiya S. A systematic review of risk factors of adverse drug reactions in hospitalized patients. *Asian Journal of Pharmaceutical and Clinical Research*. 2018 Oct 1;11(10):25–9.
43. Smyth RMD, Gargon E, Kirkham J, Cresswell L, Golder S, Smyth R, et al. Adverse drug reactions in children-A systematic review. Vol. 7, *PLoS ONE*. 2012.
44. Lovia S, Sari YO, Almasdy D, Amelin F. Studi Kualitatif Pengetahuan Perawat terhadap Reaksi Obat yang Tidak Dikehendaki (ROTD) di Bangsal

Rawat Inap Anak RSUP Dr. M. Djamil Padang. *Jurnal Sains Farmasi & Klinis*. 2019 Aug 29;6(2):95.

45. Eaddy Norton A, Broyles AD. Drug allergy in children and adults: Is it the double X chromosome? Vol. 122, *Annals of Allergy, Asthma and Immunology*. American College of Allergy, Asthma and Immunology; 2019. p. 148–55.
46. Leffler J, Stumbles PA, Strickland DH. Immunological Processes Driving IgE Sensitisation and Disease Development in Males and Females. *Int J Mol Sci* [Internet]. 2018 Jun 1 [cited 2022 Nov 24];19(6). Available from: [/pmc/articles/PMC6032271/](https://pubmed.ncbi.nlm.nih.gov/332271/)
47. Macy E, Poon K-Y T. Self-reported antibiotic allergy incidence and prevalence: age and sex effects. *Am J Med* [Internet]. 2009 Aug [cited 2022 Nov 24];122(8). Available from: <https://pubmed.ncbi.nlm.nih.gov/19635279/>
48. Mudigubba MK, Rajashekarachari Y, Dahiya S. Evaluation of Predisposing Factors Associated with Suspected Adverse Drug Reactions of Hospitalized Patients. *Journal of Young Pharmacists*. 2018 Apr 1;10(2):202–7.
49. deShazo RD, Kemp SF. Allergic Reactions to Drugs and Biologic Agents. *JAMA* [Internet]. 1997 Dec 10;278(22):1895–906. Available from: <https://doi.org/10.1001/jama.1997.03550220101014>
50. Justiz Vaillant AA, Modi P, Jan A. Atopy [Internet]. <https://www.ncbi.nlm.nih.gov/books/NBK542187/>. 2022 [cited 2022 Dec 6]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK542187/>
51. Anci E, Braun C, Marinosci A, Rodieux F, Midun E, Torres MJ, et al. Viral Infections and Cutaneous Drug-Related Eruptions. Vol. 11, *Frontiers in Pharmacology*. Frontiers Media S.A.; 2021.
52. Ahluwalia J, Wan J, Lee DH, Treat J, Yan AC. Mycoplasma-associated Stevens-Johnson syndrome in children: retrospective review of patients managed with or without intravenous immunoglobulin, systemic corticosteroids, or a combination of therapies. *Pediatr Dermatol* [Internet]. 2014 Nov 1 [cited 2022 Dec 9];31(6):664–9. Available from: <https://pubmed.ncbi.nlm.nih.gov/25424206/>
53. Knight L, Muloiwa R, Dlamini S, Lehloenya RJ. Factors associated with increased mortality in a predominantly HIV-infected population with Stevens Johnson syndrome and toxic epidermal necrolysis. *PLoS One* [Internet]. 2014 Apr 2 [cited 2022 Dec 9];9(4). Available from: <https://pubmed.ncbi.nlm.nih.gov/24695805/>
54. Pichler WJ. Consequences of drug binding to immune receptors: Immune stimulation following pharmacological interaction with immune receptors

(T-cell receptor for antigen or human leukocyte antigen) with altered peptide-human leukocyte antigen or peptide. Vol. 31, *Dermatologica Sinica*. 2013. p. 181–90.

55. Nayak S, Acharjya B. ADVERSE CUTANEOUS DRUG REACTION. *Indian J Dermatol* [Internet]. 2008 Jan 1 [cited 2022 Dec 10];53(1):2. Available from: /pmc/articles/PMC2784579/
56. Hausmann O, Schnyder B, Pichler WJ. Etiology and pathogenesis of adverse drug reactions. *Chem Immunol Allergy*. 2012 May;97:32–46.
57. Abbas AK, Litchman AH, Pillai S. *Imunologi Dasar Abbas: Fungsi dan Kelainan Sistem Imun*. indonesia kelima. Kalim H, editor. Singapore: Elsevier Singapore Pte Ltd; 2016.
58. Baratawidjaja KG, Rengganis Iris. *Imunologi Dasar*. Edisi ke-10. Badan Penerbit Fakultas Kedokteran Universitas Indonesia; 2018.
59. Viel S, Pescarmona R, Belot A, Nosbaum A, Lombard C, Walzer T, et al. A case of type 2 hypersensitivity to rasburicase diagnosed with a Natural Killer cell activation assay. *Front Immunol*. 2018 Jan 29;9(JAN).
60. Mosser DM, Zhang X. Measuring Opsonic Phagocytosis via Fcγ Receptors and Complement Receptors on Macrophages. *Current protocols in immunology* / edited by John E Coligan . [et al] [Internet]. 2011 [cited 2022 Dec 26];CHAPTER(SUPPL. 95):Unit. Available from: /pmc/articles/PMC3465686/
61. Bajwa SF, Mohammed RH. Type II Hypersensitivity Reaction. *StatPearls* [Internet]. 2022 Sep 5 [cited 2023 Jan 3]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK563264/>
62. Smith TJ, Hegedüs L. Graves' Disease. Longo DL, editor. *New England Journal of Medicine* [Internet]. 2016 Oct 20;375(16):1552–65. Available from: <http://www.nejm.org/doi/10.1056/NEJMra1510030>
63. Uzzaman A, Cho SH. Classification of hypersensitivity reactions. *Allergy Asthma Proc* [Internet]. 2012 May 1;33(3):96–9. Available from: <http://www.ingentaconnect.com/content/10.2500/aap.2012.33.3561>
64. Baratawidjaja KG, Rengganis I. *Alergi Dasar*. Interna Publishing; 2009.
65. Mockenhaupt M. Introduction: Classification, Terminology, Epidemiology, and Etiology of Cutaneous Adverse Drug Reactions. In: *Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions*. Springer Singapore; 2019. p. 3–20.
66. Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, et al. *Fitzpatrick's Dermatology*. 9th Ed. Vol. I. McGraw-Hill Education; 2019.

67. Brahimi N, Routier E, Raison-Peyron N, Tronquoy AF, Pouget-Jasson C, Amarger S, et al. A three-year-analysis of fixed drug eruptions in hospital settings in France. *Eur J Dermatol* [Internet]. 2010 Jul [cited 2023 Jan 24];20(4):461–4. Available from: <https://pubmed.ncbi.nlm.nih.gov/20507840/>
68. Patell RD, Dosi V, Shah PC, Joshi HS, Rushad D, Patell D. Widespread bullous fixed drug eruption. 2014; Available from: <http://group.bmj.com/group/rights-licensing/permissions>.
69. Shavit E, Alavi A, Sibbald RG. Vasculitis—What Do We Have to Know? A Review of Literature. *Int J Low Extrem Wounds* [Internet]. 2018 Dec 3;17(4):218–26. Available from: <http://journals.sagepub.com/doi/10.1177/1534734618804982>
70. Bastuji-Garin S. Clinical Classification of Cases of Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome, and Erythema Multiforme. *Arch Dermatol* [Internet]. 1993 Jan 1;129(1):92. Available from: <http://archderm.jamanetwork.com/article.aspx?doi=10.1001/archderm.1993.01680220104023>
71. Grünwald P, Mockenhaupt M, Panzer R, Emmert S. Erythema multiforme, Stevens-Johnson syndrome/toxic epidermal necrolysis – diagnosis and treatment. Vol. 18, *JDDG - Journal of the German Society of Dermatology*. Wiley-VCH Verlag; 2020. p. 547–53.
72. Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): A review and update. *J Am Acad Dermatol* [Internet]. 2015 Nov 1;73(5):843–8. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0190962215019313>
73. Martínez-Cabriales SA, Rodríguez-Bolaños F, Shear NH. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): How Far Have We Come? Vol. 20, *American Journal of Clinical Dermatology*. Springer International Publishing; 2019. p. 217–36.
74. Khan DA. Cutaneous drug reactions. *Journal of Allergy and Clinical Immunology* [Internet]. 2012 Nov;130(5):1225-1225.e6. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0091674912012985>
75. Picard D, Janela B, Descamps V, D’Incan M, Courville P, Jacquot S, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): A multiorgan antiviral T cell response. *Sci Transl Med*. 2010 Aug 25;2(46).
76. Wolff K, Johnson RA, Saavedra AP, Roh EK. *Fitzpatrick’s Color Atlas And Synopsis of Clinical Dermatology*. 8th Edition. McGraw-Hill Education; 2017.

77. Harr T. Diagnostic Approach to Drug Allergy. In: Chem Immunol Allergy Basel, Karger [Internet]. 2012. p. 47–60. Available from: <https://www.karger.com/Article/FullText/335615>
78. Widaty S, Soebono H, Nilasari H, Listiawan Y, Siswati AS, Triwahyudi D, et al. Panduan Keterampilan Klinis Bagi Dokter Spesialis Kulit dan Kelamin di Indonesia [Internet]. Perhimpunan Dokter Spesialis Kulit dan Kelamin Indonesia (PERDOSKI); 2017 [cited 2023 Jan 31]. Available from: <https://perdoski.id/uploads/original/2017/09/PanduanKeterampilanKlinisPERDOSKI2017.pdf>
79. Mayorga C, Celik G, Rouzair P, Whitaker P, Bonadonna P, Rodrigues-Cernadas J, et al. In vitro tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper. *Allergy: European Journal of Allergy and Clinical Immunology*. 2016 Aug 1;71(8):1103–34.
80. Pandapotan RA, Rengganis I. Pendekatan Diagnosis dan Tata Laksana Alergi Obat. *Jurnal Penyakit Dalam Indonesia* [Internet]. 2017 Mar 30;4(1):45. Available from: <http://jurnalpenyakitdalam.ui.ac.id/index.php/jpdi/article/view/113>
81. Budianti WK, Pradana P, Ramadhiani M. Peran Dan Prosedur Uji Kulit Untuk Identifikasi Penyebab Pada Kasus Reaksi Simpang Obat. *Media Dermato Venereologica Indonesiana* [Internet]. 2019 May 9;45(3). Available from: <https://ojs3.perdoski.id/index.php/mdvi/article/view/34>
82. Heinzerling L, Mari A, Bergmann KC, Bresciani M, Burbach G, Darsow U, et al. The skin prick test - European standards. *Clin Transl Allergy*. 2013 Feb 1;3(1):1–10.
83. Dworzynski K, Ardern-Jones M, Nasser S. Diagnosis and management of drug allergy in adults, children and young people: Summary of NICE guidance. Vol. 349, *BMJ (Online)*. BMJ Publishing Group; 2014.
84. Phillips GS, Wu J, Hellmann MD, Postow MA, Rizvi NA, Freites-Martinez A, et al. Treatment Outcomes of Immune-Related Cutaneous Adverse Events. *J Clin Oncol* [Internet]. 2019;37:2746–58. Available from: <https://doi>.
85. Marzano A v., Borghi A, Cugno M. Adverse drug reactions and organ damage: The skin. *Eur J Intern Med*. 2016 Mar 1;28:17–24.
86. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: A Severity-of-Illness Score for Toxic Epidermal Necrolysis. *Journal of Investigative Dermatology* [Internet]. 2000 Aug;115(2):149–53. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0022202X1540939X>

87. Badan Pusat Statistik. Statistik Indonesia 2023.
88. Makmur O, Anggraini YE, Nugraha DP. Erupsi Obat Alergi di Poliklinik Kulit dan Kelamin RSUD Arifin Achmad (2011-2015). *Jurnal Kesehatan Melayu*. 2018 Apr 25;1(2):51.
89. RSUP Dr. M. Djamil Padang. Laporan Tahunan RSUP Dr. M. Djamil Padang Tahun 2022. Padang; 2023.
90. RSUP Dr. M. Djamil Padang. Laporan Kinerja Instansi Pemerintah RSUP Dr. M. Djamil Tahun 2021. Padang; 2022.
91. Isyroqiyah NM, Soegiarto G, Setiawati Y. Profile of Drug Hypersensitivity Patients Hospitalized in Dr. Soetomo Hospital, Surabaya, Indonesia: Preliminary Data of 6 Months Observation. *Folia Medica Indonesiana*. 2019 Apr 9;55(1):54.
92. Darmani EH, Indah S As TSyD, Anggraini YE, Makmur O. Gambaran Karakteristik Pasien Erupsi Obat Alergi di RSUD Arifin Achmad Pekanbaru Periode 2010 – 2014. *Jurnal Ilmu Kedokteran* [Internet]. 2017 Dec 29;10(1):67. Available from: <http://jik.fk.unri.ac.id/index.php/jik/article/view/83>
93. Yadesa TM, Kitutu FE, Deyno S, Ogowang PE, Tamukong R, Alele PE. Prevalence, characteristics and predicting risk factors of adverse drug reactions among hospitalized older adults: A systematic review and meta-analysis. *SAGE Open Med* [Internet]. 2021 Jan 18;9. Available from: <http://journals.sagepub.com/doi/10.1177/20503121211039099>
94. Irawan B, Ainy A. Analisis Faktor-Faktor Yang Berhubungan Dengan Pemanfaatan Pelayanan Kesehatan Pada Peserta Jaminan Kesehatan Nasional Di Wilayah Kerja Puskesmas Payakabung, Kabupaten Ogan Ilir. *Jurnal Ilmu Kesehatan Masyarakat* [Internet]. 2018 Nov 5;9(3):189–97. Available from: <http://ejournal.fkm.unsri.ac.id/index.php/jikm/article/view/311>
95. Tian XY, Liu B, Shi H, Zhao ZR, Zhou XP, Zhang T, et al. Incidence of adverse cutaneous drug reactions in 22,866 Chinese inpatients: a prospective study. *Arch Dermatol Res*. 2015 Nov 1;307(9):829–34.
96. Klein SL, Marriott I, Fish EN. Sex-based differences in immune function and responses to vaccination. *Trans R Soc Trop Med Hyg* [Internet]. 2015 Jan 1;109(1):9–15. Available from: <https://academic.oup.com/trstmh/article-lookup/doi/10.1093/trstmh/tru167>
97. Heelan K, Cathryn S, Neil H S. Cutaneous Reaction to Drugs. In: Fitzpatrick's Dermatology. 9th Ed. McGraw-Hill Education; 2019. p. 749–62.

98. Zalewska-Janowska A, Spiewak R, Kowalski ML. Cutaneous Manifestation of Drug Allergy and Hypersensitivity. Vol. 37, Immunology and Allergy Clinics of North America. W.B. Saunders; 2017. p. 165–81.
99. Stern RS. clinical practice Exanthematous Drug Eruptions. Vol. 366, N Engl J Med. 2012.
100. Mockenhaupt M, Roujeau JC. Epidermal Necrolysis (Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis). In: Fitzpatrick's Dermatology. 2019. p. 733.
101. Anggarini DR, Rosita C, Prakoeswa S. Penatalaksanaan Pasien Erupsi Obat di Instalasi Rawat Inap (IRNA) Kesehatan Kulit dan Kelamin RSUD Dr. Soetomo Surabaya: Studi Retrospektif. Berkala Ilmu Kesehatan Kulit dan Kelamin. 2013;25(3):141–8.
102. Klein EY, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA, et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci U S A. 2018;115(15):E3463–70.
103. Limato R, Lazarus G, Dernison P, Mudia M, Alamanda M, Nelwan EJ, et al. Optimizing antibiotic use in Indonesia: a systematic review and synthesis of current evidence to inform opportunities for intervention. medRxiv [Internet]. 2022 Jan 1;2022.02.20.22271261. Available from: <http://medrxiv.org/content/early/2022/02/21/2022.02.20.22271261.abstract>
104. Kementerian Kesehatan Republik Indonesia. Riset Kesehatan Dasar Tahun 2013. Jakarta; 2013.
105. Pavlos R, Mallal S, Ostrov D, Buus S, Metushi I, Peters B, et al. T Cell–Mediated Hypersensitivity Reactions to Drugs. Annu Rev Med. 2015 Jan 14;66(1):439–54.
106. Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. Vol. 393, The Lancet. Lancet Publishing Group; 2019. p. 183–98.
107. Mariana N, Dinar Widiartari A, Taufik M, Wijaya C, Sarry Hartono T, Oto Wijaya S, et al. Gambaran Kuantitatif Antibiotik Berdasarkan Metode Defined Daily Dose di RSPI Sulianti Saroso Pada Januari-Juni 2019. PHARMACEUTICAL JOURNAL OF INDONESIA [Internet]. 2021;7(1):37–42. Available from: <http://.pji.ub.ac.id>
108. Kim HK, Kim DY, Bae EK, Kim DW. Adverse skin reactions with antiepileptic drugs using Korea adverse event reporting system database, 2008-2017. J Korean Med Sci. 2020 Feb 3;35(4).
109. Lee HY, Martanto W, Thirumoorthy T. Epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in Southeast Asia. Vol. 31, Dermatologica Sinica. 2013. p. 217–20.

110. Hidajat D, Luh N, Lindriati PN, Wy N, Purwaningsih D. Reaksi Hipersensitivitas pada Kulit Akibat Obat Anti Inflamasi Non Steroid. *Jurnal Kedokteran*. 2019(3):6–13.
111. Kementerian Kesehatan Republik Indonesia. Laporan Riskesdas 2018 Nasional. Jakarta; 2019.
112. Daryabor G, Atashzar MR, Kabelitz D, Meri S, Kalantar K. The Effects of Type 2 Diabetes Mellitus on Organ Metabolism and the Immune System. Vol. 11, *Frontiers in Immunology*. Frontiers Media S.A.; 2020.
113. Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. *Circulation* [Internet]. 2016 Jun 14 [cited 2023 Sep 4];133(24):2459–502. Available from: <https://pubmed.ncbi.nlm.nih.gov/27297342/>
114. Singh P, Sharma RK, Singh J. Study of Prescribing Pattern and Adverse Drug Reactions in Hypertensive Patients with Comorbidities as per JNC 8 Hypertension Guidelines in a Tertiary Care Hospital of Punjab. *Journal of Evidence Based Medicine and Healthcare*. 2020 May 6;7(19):931–7.
115. Hosohata K, Inada A, Oyama S, Niinomi I, Wakabayashi T, Iwanaga K. Adverse Cutaneous Drug Reactions Associated with Old- and New-Generation Antiepileptic Drugs Using the Japanese Pharmacovigilance Database. *Clin Drug Investig*. 2019 Apr 1;39(4):363–8.
116. Kelompok Studi Epilepsi Perhimpunan Dokter Spesialis Saraf Indonesia (PERDOSSI). *Pedoman Tatalaksana Epilepsi*. 6th ed. Kusumastuti K, Gunadharma S, Kustiowati E, editors. Surabaya: Airlangga University Press; 2019. 20–21 p.
117. Mullan KA, Anderson A, Illing PT, Kwan P, Purcell AW, Mifsud NA. HLA-associated antiepileptic drug-induced cutaneous adverse reactions. *HLA*. 2019 Jun 9;93(6):417–35.
118. George DM, Palatty PL. Pattern of adverse drug reactions to anticancer drugs at an apex hospital in south India: A retrospective study. *Indian Journal of Pharmacy and Pharmacology*. 2022 Aug 28;9(3):191–5.
119. Everson TM, Lyons G, Zhang H, Soto-Ramírez N, Lockett GA, Patil VK, et al. DNA methylation loci associated with atopy and high serum IgE: A genome-wide application of recursive Random Forest feature selection. *Genome Med*. 2015 Aug 21;7(1).
120. Ogulur I, Pat Y, Ardicli O, Barletta E, Cevhertas L, Fernandez-Santamaria R, et al. Advances and highlights in biomarkers of allergic diseases. *Allergy*:

European Journal of Allergy and Clinical Immunology. 2021 Dec 1;76(12):3659–86.

121. Frantz R, Huang S, Are A, Motaparathi K. Stevens–johnson syndrome and toxic epidermal necrolysis: A review of diagnosis and management. *Medicina (Lithuania)*. 2021 Sep 1;57(9).
122. Hsieh MH, Watanabe T, Aihara M. Recent Dermatological Treatments for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Japan. Vol. 8, *Frontiers in Medicine*. Frontiers Media S.A.; 2021.
123. Zimmermann S, Sekula P, Venhoff M, Motschall E, Knaus J, Schumacher M, et al. Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis. *JAMA Dermatol* [Internet]. 2017 Jun 1 [cited 2023 Sep 7];153(6):514. Available from: [/pmc/articles/PMC5817620/](#)
124. Roongpisuthipong W, Prompongsa S, Klangjareonchai T. Retrospective Analysis of Corticosteroid Treatment in Stevens-Johnson Syndrome and/or Toxic Epidermal Necrolysis over a Period of 10 Years in Vajira Hospital, Navamindrathiraj University, Bangkok. *Dermatol Res Pract* [Internet]. 2014 [cited 2023 Sep 7];2014. Available from: [/pmc/articles/PMC4082840/](#)
125. Wahyu Rahmawati Y, Mira Indramaya D. Studi Retrospektif: Sindrom Stevens-Johnson dan Nekrolisis Epidermal Toksik. *Berkala Ilmu Kesehatan Kulit dan Kelamin*. 2016;
126. Anandabaskar N. Protein Synthesis Inhibitors. In: *Introduction to Basics of Pharmacology and Toxicology*. Singapore: Springer Nature Singapore; 2021. p. 835–68.
127. Priyadarshini R, Raj GM. Histamine, Serotonin, Bradykinin, and the Ergot Alkaloids. In: *Introduction to Basics of Pharmacology and Toxicology*. Singapore: Springer Nature Singapore; 2021. p. 283–312.
128. Ince M, Ruether P. Histamine and antihistamines. *Anaesthesia & Intensive Care Medicine*. 2021 Nov;22(11):749–55.
129. Rakhmania H, Setiadhi R. Toxic epidermal necrolysis dipicu oleh parasetamol dan kloramfenikol. *Clinical Dental Journal) UGM*. 2018;4(3).
130. Evangeline H, Supriadi D, Sunarya W. Perbedaan Kompres Nacl 0,9% dengan Kompres Alkohol 70% Terhadap Penurunan Intensitas Nyeri Pada Pasien Flebitis. *Jurnal Kedokteran dan Kesehatan*. 2015 Oct;2(3):245–51.